Patenting Human Embryonic Stem Cells in the EU
This article was originally published in SRA
As is common with many new technologies, there are challenges involved in attempting to patent new developments in the field of biotechnology and, in particular, in stem cell technology. Not least, there are ethical and moral questions surrounding the artificial creation of life or cloning, and concerning human dignity and the right to life. There is also debate over balancing the destruction of embryos against the need to develop potential therapeutic agents. Such questions have, unsurprisingly, fed through into the realms of stem cell patenting, since patenting goes directly to the heart of commercialising technology.
You may also be interested in...
Rutgers University professor testifies in support of bill directing the FDA to designate National Centers of Excellence in Continuous Manufacturing; other bills target generic labeling, orphan exclusivity and counterfeit devices.
Roche receives initial knockback for lymphoma treatment which could rival CAR-T therapies.
Parliamentary debate next week on the post-Brexit regulatory adjustments ahead for the UK medical devices industry will coincide with the opening of post-Brexit EU trade talks by the UK government. After a period of nervous calm, Brexit will be back with a bang.